ArticleMedicine2025
Uncovering the gut microbiota's role in temporomandibular joint disorders: A bidirectional Mendelian randomization study.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Previous studies have revealed the association between gut microbiota (GM) and temporomandibular joint inflammation, which leads to temporomandibular joint disorders (TMD). However, the causality of the associations remains unknown. This Mendelian randomization (MR) study aims to clarify the causal relationships between GM and TMD. We employed a two-sample MR approach to analyze GM data from the MiBioGen consortium, including 18,340 participants and 211 taxa, and TMD data from the FinnGen consortium R10 release, including 6314 cases and 222,498 controls. Various MR methods, including inverse-variance weighted (IVW), MR-Egger, and weighted median analyses, alongside comprehensive sensitivity analyses, were used to assess causality. After comprehensive sensitivity analyses, the study found causal links between 6 certain GM at the genus level and TMD, including Eubacterium fissicatena group (IVW's odds ratio [OR] = 1.18; 95% confidence interval [CI]: 1.02-1.37; P = .027), Catenibacterium (IVW's OR = 1.33; 95% CI: 1.11-1.59; P = .002), Oxalobacter (IVW's OR = 0.85; 95% CI: 0.75-0.97; P = .013), Ruminococcaceae NK4A214 (IVW's OR = 0.80; 95% CI: 0.66-0.99; P = .036), and Senegalimassilia (IVW's OR = 0.75; 95% CI: 0.59-0.96; P = .024). Following replication verification analysis, Catenibacterium (FDR = .04) at the genus level were positively correlated to the risk of TMD. The reverse MR analysis revealed that TMD had no significant effect on the 6 GMs. The findings of this MR study support a strong and negative causal association between genus Catenibacterium and TMD, highlighting potential targets for the prevention and treatment of TMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.